Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
Authors
Keywords
-
Journal
LANCET
Volume 397, Issue 10275, Pages 682-694
Publisher
Elsevier BV
Online
2021-01-30
DOI
10.1016/s0140-6736(21)00241-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cell entry mechanisms of SARS-CoV-2
- (2020) Jian Shang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
- (2020) Yuan Huang et al. ACTA PHARMACOLOGICA SINICA
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- Immune-mediated approaches against COVID-19
- (2020) Helena F. Florindo et al. Nature Nanotechnology
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
- (2020) Carolyn Rydyznski Moderbacher et al. CELL
- SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
- (2020) Gregory A Poland et al. LANCET
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity
- (2019) Shuting Shi et al. VACCINE
- Safety of AS03-adjuvanted influenza vaccines: A review of the evidence
- (2019) Catherine Cohet et al. VACCINE
- Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy
- (2018) Guo Luo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
- (2012) Scott A. Halperin et al. VACCINE
- Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
- (2012) Sandrine Belouzard et al. Viruses-Basel
- Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study
- (2011) Joanne M. Langley et al. JOURNAL OF INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More